Premium
Expression of CRl and CR2 Complement Receptors following Epstein‐Barr Virus Infection of Burkitt's Lymphoma Cell Lines
Author(s) -
COHEN J. H. M.,
FISCHER E.,
KAZATCHKINE M. D.,
LENOIR G. M.,
LEFEVREDHLVINCOURT C.,
REVILLARD J.P.
Publication year - 1987
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1987.tb01085.x
Subject(s) - receptor , epstein–barr virus , biology , virus , complement receptor , antibody , cell culture , virology , lymphoma , microbiology and biotechnology , rosette (schizont appearance) , flow cytometry , b cell , burkitt's lymphoma , immunology , complement system , biochemistry , genetics
Epstein‐Barr virus (EBV) infection of human B lymphocvtes involves a specific receptor closely associated with, or identical to, the C3d complement receptor, CR2, Thus. 25 out of 29 EBV‐positive Burkilt's lymphuma (BL) cell lines but none of 15 EBV‐negative BL lines were found to express C3 receptors. Furthermore, in vitro in association with EBV of six EBV‐negative cell lines resulted in the expression of C3 receptors in association with that of EBV‐determined nuclear antigen (EBNA). Rosette assays using erythrocytes coated with human C3b, C3bi, and C3d, inhibition of rosette formation with anti‐receptor antibodies, and flow cytometry analysis of stained cells demonstrated that EBV‐converted lines expressed C3b ami C3d receptors, CRl and CR2. Anti‐receptor antibodies recognized an average of40,700 anti‐CR1 and 140,000 anti‐CR2 binding sites on an EBV‐converted line(BL41/B95), whereas no specifie binding occurred on the corresponding EBV‐negative (BL41) cells, Because CR1 and CR2 are involved in B‐cell proliferation and/or differcntiation, enhanced expression of C3 receptors following the interaction between EBV and B celK and/or subsequent infection of the cells by EBV may provide a basis for positive control of B lymphocyte proliferation by EBV.